Shares of Valeant Pharmaceuticals International Inc. climbed Wednesday after the Canadian drugmaker said it expects market share gains in most of its businesses and that its third-quarter revenue will top forecasts. The drugmaker also said it expects 10 percent growth from the established business of its contact lens maker Bausch + Lomb, a target of criticism in Valeant's on-going takeover battle with Botox-maker Allergan Inc. Allergan has rebuffed several takeover bids from Valeant over the past few months, the latest amounting to about $53 billion.